PRKCB and neoplasm: Another way to disrupt CLL/MSC crosstalk and overcoming drug resistance in CLL patients is to directly target PKC-β signaling pathway in MSC: indeed, Park et al. showed that small-molecule PKC-β inhibitors antagonize prosurvival signals from stromal cells and sensitize tumor cells to targeted and non-targeted chemotherapy, resulting in enhanced cytotoxicity (162).